



INVESTOR
PRESENTATION
October 2022

Forward Looking Statements

This presentation has been prepared by Movano Inc. (“we,” “us,” “our,” “Movano” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither this presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; product development efforts and product releases; clinical trial and regulatory initiatives; commercial partner activities; as well as our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investment Summary



- › We are at the **intersection** of **med tech** and **consumer device**
- › **Proprietary RF** tech drives blood pressure and glucose features on future products
- › **Capital efficient** and **disciplined** operating culture



First ring is foundational, launching D2C 1H23

- › **Women are underserved** in healthcare
- › Movano's ring generated **2 billion impressions** post CES 2022
- › **FDA clearances** (e.g., HR, SpO₂, RR) unlock incremental channel opportunity



There is a health crisis in America

The US spent **\$4.2T** on healthcare in 2020, almost 20% of GDP.¹

Approximately **96M** American adults have **prediabetes**.² Of those with prediabetes, more than 80% are unaware.³

130M Americans live with chronic illness, expected to be **170M** by 2030.⁴

(1) [Cms.gov](https://www.cms.gov)
(2) [Health For Life, aha.org](https://www.aha.org)
(3) [Prediabetes – Your Chance to Prevent Prediabetes, cdc.gov](https://www.cdc.gov)
(4) [Health For Life, aha.org](https://www.aha.org)

Covid-19 Accelerated Proactive Health Tracking¹



Consumers are looking for a solution to help them prevent disease and monitor conditions.



(1) How COVID-19 has pushed companies over the technology tipping point—and transformed business forever, McKinsey

The intersection of consumer & medical devices



Competitive Advantages




Uniquely designed for women

Medical-grade accuracy


Meaningful & actionable insights

Expert resources & community



Women are adversely affected by the state of healthcare

- › Women have been excluded in scientific and medical research. ¹
- › While more connected to the healthcare system, most feel dismissed by providers. ²
- › Heart disease is the #1 cause of death for women in the U.S. ³
- › Rates of hypertension and diabetes are approximately twice that for women of color than white women. ⁴
- › 92% of women feel unprepared for menopause. ⁵



Women's health and wellness market is set to grow to \$50B by 2025⁶

(1) [NIH Revitalization Plan of 1993](#)
(2) [Women Feel More Dismissed by Doctors During Pandemic](#), bizjournals.com
(3) [Lower Your Risk For the Number One Killer of Women](#), cdc.gov
(4) [Racial and Ethnic Disparities in Women's Health Coverage and Access to Care](#)
(5) [Women Are Unprepared For Menopause](#), Fortune Well
(6) [Frost & Sullivan, FemTech Report, 2019](#)

Who we spoke to:

**1000
Women**

Between the ages of 35 and 75 in a series of 20-minute interviews

- › Currently own or looking to purchase a wearable
- › Nationally representative sample who live in the U.S.



15 women

In a three-day discussion board focus group

8 women

For 90-minute in-depth interviews for identification of key user journeys

What they told us:



The world is her gym - she is not interested in heavy workouts or focused on dieting and calories.



She is seeking out safe and trusted resources to better understand her overall health metrics.



She is looking for **control** of her health - **more energy, strength, and enough sleep** to stay on top of daily tasks.



Media response is overwhelmingly positive

“Metrics such as heart rate, heart rate variability and sleep can be tracked in tandem with steps and calories burnt, while its svelte design may well make it **the most fashion-focused smart ring around.**” — Runner’s World

“One thing it definitely seems to **have nailed is the design**, judging by its promotional images, which show rings in three designs and four tasteful metallic colors.”

-techradar.com

“—then this is a **huge step forward from fun little dongles that can count your steps.**”

- wired.com

“Running parallel to the user experience is **Movano’s commitment to making the smart ring a compelling product for women.**”

-Digital Trends

Movano looks like it could be **real competition for Oura.**”

- mashable.com

“The Movano Ring is a **mouth-watering proposition...**”

- wearable.com

WSJ

WIRED

TE TechCrunch

THE VERGE

Mashable





**We are a
medical
device
company**

Differentiated Infrastructure



Quality Management System &
QRC Team



FDA-Compliant Contract
Manufacturer



Clinical Lab for IRB-Approved
Studies

Operating at a Higher Standard



Design Control & Risk
Management Procedures



HIPAA-Compliant Systems

Hypoxia Study Results



Heart Rate & Blood Oxygen

Subject	HR RMSE			SpO2 RMSE		
	Nelcor	MoveTip	MoveRing	Nelcor	MoveTip	MoveRing
1	1.34	1.02	1.02	2.62	2.22	1.75
2	2.24	2.60	6.88	1.97	2.17	2.52
3	2.04	1.58	1.92	3.02	2.30	3.00
4	1.71	1.46	1.51	2.60	3.17	2.48
5	2.07	1.41	0.93	3.97	2.91	1.95
6	1.20	0.89	NaN ¹	1.71	1.86	NaN ¹
7	1.45	1.44	1.37	2.25	1.97	2.69
Mean	1.72	1.49	2.27	2.59	2.37	2.40


Test Parameters:

- Same protocol as required for FDA submission
- FDA requires SpO2 RMSE <4%
- HR (at rest) accuracy in line with FDA standards
- Massimo reference device

(1) NaN = Patient 6 data was corrupted in transit to clinical data acquisition system.



Unlocks multiple strategic opportunities



Our ring addresses unique needs for strategic partners



Med device companies

- FDA-cleared wearables to enhance in-house solutions.

Pharmaceutical companies

- Medical-grade data for clinical trial and post-market surveillance.


Healthcare networks

- Improving remote care through visibility into daily health metrics.

Universities

- Enhancing and tracking athlete recovery.

Planned Launch Timeline: First Ring





Long-term vision: Movano ecosystem

Hardware as an enabler to tailored mobile app experiences



Future Device(s) & Analytes: BP, Glucose, etc.



Cloud platform with AI

MOVANO HEALTH PLATFORM

Third Party (3P) Integrations



3P Hardware (e.g., connected scales, mattresses, waterbottles)



EMR Systems (e.g., Epic, Cerner)




Healthcare Service Providers (e.g., Payors, LabCorp)



Mobile ecosystem datasets (e.g., Apple Healthkit, Google HealthConnect)

THE POWER OF 4 ICs IN 1

Meet Movano's custom
mmWave integrated sensor



Our patented System-on-a-Chip was built from the ground up

After four years in development, the smallest ever custom RF-enabled IC designed for blood pressure and glucose monitoring is now functional, providing:

Greater accuracy

Flexibility in form factor

Cost-effective solutions




Actual chip size: 4mm x 6.7mm



Movano patent summary

US: 11 Issued
41 Pending
OUS: 5 Pending



Our patents fall into three families:

RF IC Architecture

(2) Issued
(2) Pending

Covers RF IC design, including multi-band mixing and conductor loss mitigation that is critical at high frequencies.

Key Issued Patents:

- Systems for multi-band radar-based sensing (US 11,298,037)
- Methods for multi-band radar-based sending (US 10,874,314)

RF-Based Health Monitoring

(7) Issued
(29) Pending

Covers signal processing techniques for generating high resolution pulse wave signal to determine HR, BP, BG level, techniques for alignment of RF sensor, techniques related to optical/RF sensor fusion.

Key Issued Patents:

- Systems for RF-based health monitoring utilizing amplitude and phase data (US 11,445,929)
- Systems for RF-based health monitoring generating alignment signals (US 11,206,993)
- Methods and systems for monitoring BP using stepped frequency radar with spectral agility (US 11,360,188)
- Calibration, classification and localization using channel templates* (US 11,464,419, *to be issued 10/18/22)

Machine Learning Applications

(6) Pending



Techniques for generating training data and training ML models for health monitoring, and techniques for utilizing ML models for health monitoring, including blood pressure and blood glucose.

Key Patent (to be issued 10/11/22):

- Methods for training a model for use in RF-based health monitoring (US 11,464,419)

Putting our technology to the test

Measured raw arterial waveforms



Planning next
blood pressure
and glucose
studies in 2H22

Sample of Movano's RF Sensor Data & Signal Processing

Combines signals
across frequencies
and antennas

Smooths volatility while
maintaining key waveform
characteristics

Clinical Studies Timeline

2020/
2021

2022

2023

STUDIES CONDUCTED:

- Blood Glucose (N=10)
- Three (3) Blood Pressure (N=40, 45, 110)

STUDIES CONDUCTED:

- Blood Glucose (N=10)
- Hypoxia (N=7)

PLANNED STUDIES:

- Hypoxia Pivotal (N=12)
- Sleep (N=10)
- Blood Glucose (N=50-100)
- Blood Pressure (N=50-100)

PLANNED STUDIES:

- Blood Glucose (N=100)
- Blood Pressure (N=100)
- Two (2) Sleep (N=30-50; 100)

Corporate Snapshot (Nasdaq : MOVE)

Year founded: 2018

IP Portfolio: US 11 patents issued, 41 pending

OUS 5 patents pending

Dollars raised: \$80M*

Number of FTEs: 44

LTM Cash Burn 6/30/22: \$21.4M

2Q22 Cash Burn: \$6.4M

Corporate Entities: Movano Inc.

Pleasanton, CA

Movano Ireland Limited

Cork, Ireland

Cash at 6/30/22: \$21.3M

* In August 2022, the Company entered into an At the Market Issuance Agreement with B. Riley Securities, Inc. Pursuant to the terms of the Issuance Agreement, the Company may sell from time to time through the Sales Agent shares of the Company's common stock having an aggregate offering price of up to \$50M.



Our
seasoned
team has
expertise
across
critical
domains

Medtech

John Mastrototaro, PhD

CEO | DIRECTOR

Former Medtronic/MiniMed exec.
30 years medical device industry

Kim Tompkins

VP | QRC

30+ years FDA Class II/III devices,
digital health & cardiovascular

Nan Kirsten Forte

DIRECTOR

Digital health pioneer & innovator,
Exec VP and GM Everyday Health &
Former Exec VP WebMD

Technology

Michael Leabman

FOUNDER & CTO

CTO of 4 wireless startups
20+ years smart antenna experience
200+ issued patents

Phil Kelly

SVP | ENGINEERING

Chief Scientist & SVP Systems
Engineering for wireless startups &
defense companies

Rubén Caballero

DIRECTOR

Microsoft VP Engineering,
Formerly Apple VP Engineering

Finance

J. Cogan, CFA

CFO

24 years Wall Street experience,
investor & analyst

Emily Fairbairn

CHAIR OF THE BOARD

Co-founder Ascend Capital
30+ years Wall Street experience

Brian Cullinan

DIRECTOR

2x Lead Director PwC US Board
30+ years PwC Partner

Go to Market

Tyla Bucher

CHIEF MARKETING OFFICER

20+ years building & launching global
integrated marketing campaigns for
consumer products and media
companies

Stacy Salvi, J.D.

VP | STRATEGY

Former Head of Strategic Partnerships
for Fitbit at Google

Michael Soule

VP | BUSINESS DEVELOPMENT

20+ years managing sales, strategy &
business development for consumer
product and medical device companies

Conclusion



Developing solutions at the intersection of medical and consumer devices.



D2C and B2B, given medical grade data. Our beta partners support our view of a large potential enterprise solution.



Movano Ring is our foundational product, launching 1H23. Research demonstrates women are underserved.



Proprietary RF technology is the engine that drives our blood pressure and glucose initiatives.



Significant progress alongside capital efficiency – operating culture focused on both our customers and shareholders.





NASDAQ: MOVE

+1 (415) 651-3172

6800 Koll Center Pkwy., Suite 160
Pleasanton, CA 94566

www.movano.com